All or nothing? Rethinking the FDA approval framework
The FDA recently made headlines with its controversial accelerated approval of a new treatment for Duchenne’s muscular dystrophy, a debilitating and progressive disease that affects children. Exondys 51 is the first drug to treat this disease, but there is widespread disagreement over the strength of evidence from early trials — even within the FDA.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063